Claims
- 1. A method of screening drug candidates comprising:
a) providing a cell that expresses an expression profile gene encoding CZA8 or fragment thereof; b) adding a drug candidate to said cell; and c) determining the effect of said drug candidate on the expression of said expression profile gene.
- 2. A method according to claim 1 wherein said expression profile gene encodes the CZA8 sequence of FIG. 2 (SEQ ID NO:2).
- 3. A method according to claim 1 wherein said expression profile gene encodes the CZA8 sequence of FIG. 5 (SEQ ID NO:4).
- 4. A method according to claim 1 wherein said determining comprises comparing the level of expression in the absence of said drug candidate to the level of expression in the presence of said drug candidate.
- 5. A method of screening for a bioactive agent capable of binding to CZA8 or a fragment thereof, said method comprising:
a) combining said CZA8 or a fragment thereof and a candidate bioactive agent; and b) determining the binding of said candidate agent to said CZA8 or a fragment thereof.
- 6. A method for screening for a bioactive agent capable of modulating the activity of CZA8, said method comprising:
a) combining CZA8 and a candidate bioactive agent; and b) determining the effect of said candidate agent on the bioactivity of CZA8.
- 7. A method according to claim 6 wherein said CZA8 comprises the sequence shown in FIG. 2 (SEQ ID NO:2).
- 8. A method according to claim 6 wherein said CZA8 comprises the sequence shown in FIG. 5 (SEQ ID NO:4).
- 9. A method of evaluating the effect of a candidate cancer drug comprising:
a) administering said drug to a patient; b) removing a cell sample from said patient; and c) determining the expression of a gene encoding CZA8 or fragment thereof.
- 10. A method according to claim 9 further comprising comparing said expression profile to an expression profile of a healthy individual.
- 11. A method of diagnosing cancer comprising:
a) determining the expression of a gene CZA8 or a fragment thereof in a first tissue type of a first individual; and b) comparing said expression of said gene(s) from a second normal tissue type from said first individual or a second unaffected individual; wherein a difference in said expression indicates that the first individual has cancer.
- 12. An antibody which specifically binds to CZA8 or a fragment thereof.
- 13. The antibody of claim 12, wherein said CZA8 is that shown in FIG. 2 (SEQ ID NO:2).
- 14. The antibody of claim 12, wherein said CZA8 is that shown in FIG. 5 (SEQ ID NO:4).
- 15. The antibody of claim 12, wherein said antibody is a monoclonal antibody.
- 16. The antibody of claim 12, wherein said antibody is a humanized antibody.
- 17. The antibody of claim 12, wherein said antibody is an antibody fragment.
- 18. The antibody of claim 12, wherein said antibody modulates the bioactivity of CZA8.
- 19. The antibody of claim 18, wherein said antibody is capable of inhibiting the bioactivity or neutralizing the effect of CZA8.
- 20. A method for screening for a bioactive agent capable of interfering with the binding of CZA8 or a fragment thereof and an antibody which binds to CZA8 or fragment thereof, said method comprising:
a) combining CZA8 or fragment thereof, a candidate bioactive agent and an antibody which binds to CZA8 or fragment thereof; and b) determining the binding of CZA8 or fragment thereof and said antibody.
- 21. A method according to claim 20, wherein said antibody is capable of inhibiting or neutralizing the bioactivity of CZA8.
- 22. A method for inhibiting the activity of CZA8, said method comprising binding an inhibitor to CZA8.
- 23. A method according to claim 22 wherein said inhibitor is an antibody.
- 24. A method of neutralizing the effect of CZA8 or a fragment thereof, comprising contacting an agent specific for said CZA8 or fragment thereof with said CZA8 or fragment thereof in an amount sufficient to effect neutralization.
- 25. A method of treating breast cancer and/or colorectal cancer comprising administering to a patient an inhibitor of CZA8.
- 26. A method according to claim 25 wherein said inhibitor is an antibody.
- 27. A method for localizing a therapeutic moiety to breast cancer and/or colorectal cancer tissue comprising exposing said tissue to an antibody to CZA8 or fragment thereof conjugated to said therapeutic moiety.
- 28. The method of claim 27, wherein said therapeutic moiety is a cytotoxic agent.
- 29. The method of claim 27, wherein said therapeutic moiety is a radioisotope.
- 30. A method of treating breast cancer or colorectal cancer comprising administering to an individual having said cancer an antibody to CZA8 or fragment thereof conjugated to a therapeutic moiety.
- 31. The method of claim 30, wherein said therapeutic moiety is a cytotoxic agent.
- 32. The method of claim 30, wherein said therapeutic moiety is a radioisotope.
- 33. A method for inhibiting breast cancer or colorectal cancer in a cell, wherein said method comprises administering to a cell a composition comprising antisense molecules to a nucleic acid of FIG. 1 (SEQ ID NO:1).
- 34. A method for inhibiting breast cancer or colorectal cancer in a cell, wherein said method comprises administering to a cell a composition comprising antisense molecules to a nucleic acid of FIG. 4 (SEQ ID NO:3).
- 35. A biochip comprising one or more nucleic acid segments encoding CZA8 or a fragment thereof, wherein said biochip comprises fewer than 1000 nucleic acid probes.
- 36. A method of eliciting an immune response in an individual, said method comprising administering to said individual a composition comprising CZA8 or a fragment thereof.
- 37. A method of eliciting an immune response in an individual, said method comprising administering to said individual a composition comprising a nucleic acid encoding CZA8 or a fragment thereof.
- 38. A method for determining the prognosis of an individual with breast cancer or colorectal cancer comprising determining the level of CZA8 in a sample, wherein a high level of CZA8 indicates a poor prognosis.
- 39. A polypeptide comprising the amino acid sequence as set forth in FIG. 2 (SEQ ID NO:2) or FIG. 5 (SEQ ID NO:4).
- 40. A polypeptide which is a fragment of and which comprises at least one epitope of a polypeptide having the amino acid sequence as set forth in FIG. 2 (SEQ ID NO:2) or FIG. 5 (SEQ ID NO:4).
- 41. A polypeptide having an amino acid sequence that is at least 45% identical to the amino acid sequence set forth in FIG. 2 (SEQ ID NO:2) or FIG. 5 (SEQ ID NO:4).
- 42. A polypeptide having an amino acid sequence that is at least 60% homologous to the amino acid sequence set forth in FIG. 2 (SEQ ID NO:2) or FIG. 5 (SEQ ID NO:4).
- 43. A polypeptide having an amino acid sequence that is at least 95% identical to the amino acid sequence set forth in FIG. 2 (SEQ ID NO:2) or FIG. 5 (SEQ ID NO:4).
- 44. A composition comprising the polypeptide of claim 39, 40, 41, 42 or 43 and a pharmaceutically acceptable carrier.
- 44. A nucleic acid comprising the nucleic acid sequence as set forth in FIG. 1 (SEQ ID NO:1) or FIG. 3 (SEQ ID NO:2).
- 45. A nucleic acid comprising a nucleic acid sequence encoding the polypeptide of claim 39 or 40.
Parent Case Info
[0001] This application is a continuation-in-part of U.S. Ser. No. 09/608,821 filed Jun. 30, 2000.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09608821 |
Jun 2000 |
US |
Child |
09828307 |
Apr 2001 |
US |